Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan

Akira Morimoto, Yasushi Ishida, Nobuhiro Suzuki, Shoichi Ohga, Yoko Shioda, Yuri Okimoto, Kazuko Kudo, Eiichi Ishii

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background. Since neither a standard treatment nor a protocol study for single-system single site (SS-s)-type Langerhans cell histiocytosis (LCH) exists, we conducted a nationwide survey in Japan to clarify the epidemiology and clinical outcome of this subtype. Procedure. Questionnaires regarding the clinical course of children with SS-s-type LCH diagnosed between 1995 and 2006 were sent to all members of the Japanese Society of Pediatric Hematology. Results. One hundred forty-six children with histologically proven SS-s LCH were evaluable. The most frequently affected organ was bone (82%), followed by skin (12%). Few patients (14%) had a CNS-RISK lesion defined by the Histiocyte Society. Patients with a skin lesion were diagnosed at a significantly younger age than patients with a bone lesion (median: 6 months vs. 5 years 11 months, P<0.001). The treatment regimen varied, but one-third of the patients in total and 71% of patients with a CNS-RISK lesion received chemotherapy that did not include etoposide. All but one patient attained remission. Ten patients (7%) showed reactivation. Of these, all eight with an initial bone lesion only exhibited reactivation in the bone(s). One patient with an initial skin lesion exhibited reactivation in the thymus. None of the patients died from disease progression or treatment complications. Conclusions. Our retrospective study, in which a relatively large proportion of the patients received chemotherapy, reveals that patients with SS-s LCH have a good prognosis. A prospective study should be conducted to confirm this and to identify the most effective and least toxic therapy for SS-s LCH.

Original languageEnglish
Pages (from-to)98-102
Number of pages5
JournalPediatric Blood and Cancer
Volume54
Issue number1
DOIs
Publication statusPublished - Jan 1 2010

Fingerprint

Langerhans Cell Histiocytosis
Japan
Bone and Bones
Skin
Surveys and Questionnaires
Drug Therapy
Histiocytes
Poisons
Etoposide
Hematology
Therapeutics
Thymus Gland
Disease Progression
Epidemiology
Retrospective Studies
Prospective Studies
Pediatrics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Morimoto, A., Ishida, Y., Suzuki, N., Ohga, S., Shioda, Y., Okimoto, Y., ... Ishii, E. (2010). Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan. Pediatric Blood and Cancer, 54(1), 98-102. https://doi.org/10.1002/pbc.22224

Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan. / Morimoto, Akira; Ishida, Yasushi; Suzuki, Nobuhiro; Ohga, Shoichi; Shioda, Yoko; Okimoto, Yuri; Kudo, Kazuko; Ishii, Eiichi.

In: Pediatric Blood and Cancer, Vol. 54, No. 1, 01.01.2010, p. 98-102.

Research output: Contribution to journalArticle

Morimoto, A, Ishida, Y, Suzuki, N, Ohga, S, Shioda, Y, Okimoto, Y, Kudo, K & Ishii, E 2010, 'Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan', Pediatric Blood and Cancer, vol. 54, no. 1, pp. 98-102. https://doi.org/10.1002/pbc.22224
Morimoto, Akira ; Ishida, Yasushi ; Suzuki, Nobuhiro ; Ohga, Shoichi ; Shioda, Yoko ; Okimoto, Yuri ; Kudo, Kazuko ; Ishii, Eiichi. / Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan. In: Pediatric Blood and Cancer. 2010 ; Vol. 54, No. 1. pp. 98-102.
@article{76bad84010684fe1b11ab6ad70b3a229,
title = "Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan",
abstract = "Background. Since neither a standard treatment nor a protocol study for single-system single site (SS-s)-type Langerhans cell histiocytosis (LCH) exists, we conducted a nationwide survey in Japan to clarify the epidemiology and clinical outcome of this subtype. Procedure. Questionnaires regarding the clinical course of children with SS-s-type LCH diagnosed between 1995 and 2006 were sent to all members of the Japanese Society of Pediatric Hematology. Results. One hundred forty-six children with histologically proven SS-s LCH were evaluable. The most frequently affected organ was bone (82{\%}), followed by skin (12{\%}). Few patients (14{\%}) had a CNS-RISK lesion defined by the Histiocyte Society. Patients with a skin lesion were diagnosed at a significantly younger age than patients with a bone lesion (median: 6 months vs. 5 years 11 months, P<0.001). The treatment regimen varied, but one-third of the patients in total and 71{\%} of patients with a CNS-RISK lesion received chemotherapy that did not include etoposide. All but one patient attained remission. Ten patients (7{\%}) showed reactivation. Of these, all eight with an initial bone lesion only exhibited reactivation in the bone(s). One patient with an initial skin lesion exhibited reactivation in the thymus. None of the patients died from disease progression or treatment complications. Conclusions. Our retrospective study, in which a relatively large proportion of the patients received chemotherapy, reveals that patients with SS-s LCH have a good prognosis. A prospective study should be conducted to confirm this and to identify the most effective and least toxic therapy for SS-s LCH.",
author = "Akira Morimoto and Yasushi Ishida and Nobuhiro Suzuki and Shoichi Ohga and Yoko Shioda and Yuri Okimoto and Kazuko Kudo and Eiichi Ishii",
year = "2010",
month = "1",
day = "1",
doi = "10.1002/pbc.22224",
language = "English",
volume = "54",
pages = "98--102",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan

AU - Morimoto, Akira

AU - Ishida, Yasushi

AU - Suzuki, Nobuhiro

AU - Ohga, Shoichi

AU - Shioda, Yoko

AU - Okimoto, Yuri

AU - Kudo, Kazuko

AU - Ishii, Eiichi

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background. Since neither a standard treatment nor a protocol study for single-system single site (SS-s)-type Langerhans cell histiocytosis (LCH) exists, we conducted a nationwide survey in Japan to clarify the epidemiology and clinical outcome of this subtype. Procedure. Questionnaires regarding the clinical course of children with SS-s-type LCH diagnosed between 1995 and 2006 were sent to all members of the Japanese Society of Pediatric Hematology. Results. One hundred forty-six children with histologically proven SS-s LCH were evaluable. The most frequently affected organ was bone (82%), followed by skin (12%). Few patients (14%) had a CNS-RISK lesion defined by the Histiocyte Society. Patients with a skin lesion were diagnosed at a significantly younger age than patients with a bone lesion (median: 6 months vs. 5 years 11 months, P<0.001). The treatment regimen varied, but one-third of the patients in total and 71% of patients with a CNS-RISK lesion received chemotherapy that did not include etoposide. All but one patient attained remission. Ten patients (7%) showed reactivation. Of these, all eight with an initial bone lesion only exhibited reactivation in the bone(s). One patient with an initial skin lesion exhibited reactivation in the thymus. None of the patients died from disease progression or treatment complications. Conclusions. Our retrospective study, in which a relatively large proportion of the patients received chemotherapy, reveals that patients with SS-s LCH have a good prognosis. A prospective study should be conducted to confirm this and to identify the most effective and least toxic therapy for SS-s LCH.

AB - Background. Since neither a standard treatment nor a protocol study for single-system single site (SS-s)-type Langerhans cell histiocytosis (LCH) exists, we conducted a nationwide survey in Japan to clarify the epidemiology and clinical outcome of this subtype. Procedure. Questionnaires regarding the clinical course of children with SS-s-type LCH diagnosed between 1995 and 2006 were sent to all members of the Japanese Society of Pediatric Hematology. Results. One hundred forty-six children with histologically proven SS-s LCH were evaluable. The most frequently affected organ was bone (82%), followed by skin (12%). Few patients (14%) had a CNS-RISK lesion defined by the Histiocyte Society. Patients with a skin lesion were diagnosed at a significantly younger age than patients with a bone lesion (median: 6 months vs. 5 years 11 months, P<0.001). The treatment regimen varied, but one-third of the patients in total and 71% of patients with a CNS-RISK lesion received chemotherapy that did not include etoposide. All but one patient attained remission. Ten patients (7%) showed reactivation. Of these, all eight with an initial bone lesion only exhibited reactivation in the bone(s). One patient with an initial skin lesion exhibited reactivation in the thymus. None of the patients died from disease progression or treatment complications. Conclusions. Our retrospective study, in which a relatively large proportion of the patients received chemotherapy, reveals that patients with SS-s LCH have a good prognosis. A prospective study should be conducted to confirm this and to identify the most effective and least toxic therapy for SS-s LCH.

UR - http://www.scopus.com/inward/record.url?scp=73349095407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349095407&partnerID=8YFLogxK

U2 - 10.1002/pbc.22224

DO - 10.1002/pbc.22224

M3 - Article

VL - 54

SP - 98

EP - 102

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -